Introduction {#Sec1}
============

The protein kinase C family is composed of ten related serine/threonine protein kinases, which are divided into three subfamilies including conventional, novel and atypical PKCs (aPKCs). PKCζ and ι/λ represent the aPKC isoforms, where PKCι is the human and PKCλ the murine isoform. The aPKCs differ from the other PKCs by having an N-terminal PB1 domain and their activation is independent of calcium, phorbol esters and diacylglycerol (reviewed in \[[@CR1]\]). However, it has been demonstrated that the phorbol ester PMA activates PI3K and subsequently PKCζ \[[@CR2]\]. The PB1 domain of aPKCs interacts with Par6 and is important for their incorporation into the apical polarity complex which contains the Par3/Par6/aPKC module (reviewed in \[[@CR3]\]). The activity of the aPKCs is regulated by 3-phosphoinositides, phosphorylation by the phosphoinositide-dependent kinase PDK1 and through specific protein-protein interactions (reviewed in \[[@CR4]\]). Due to their strong homology (78%) it has been difficult to distinguish the individual functions of the PKCζ and ι/λ isoforms. However, PKCι/λ is ubiquitously expressed, while PKCζ has a more restricted expression pattern \[[@CR5]\]. The murine PKCλ differs only from the human PKCι at 10 out of 596 amino acid positions (98% sequence identity). PKCλ is essential for embryonic development in the mouse, whereas PKCζ-deficient mice develop nearly normally \[[@CR6]\]. Conditional knock-out studies in mice and frog have shown that PKCλ plays a role in glucose transport and induction of metabolic and diabetic syndromes \[[@CR6], [@CR7]\], and that it controls the establishment of apicobasal polarity, adherens junctions and neuroepithelial tissue architecture in early vertebrate development \[[@CR8], [@CR9]\]. Both aPKC isoforms are critical for cell survival signaling, and many studies indicate a correlation between the expression or activation of aPKC and sensitivity to apoptosis (reviewed in \[[@CR1], [@CR4]\]). The aPKCs seem to be dynamically regulated by agents inducing cell death, and recent results indicate that they may act as a switch between cell survival and cell death (reviewed in \[[@CR1], [@CR4]\]).

Transforming growth factor-β-inducible early response gene 1 (TIEG1) was originally discovered as the product of a TGFβ-inducible early response gene in human osteoblasts \[[@CR10]\]. It was later shown that overexpression of TIEG1 mimics TGFβ action and induces apoptosis and decreased proliferation in several cell lines (reviewed in \[[@CR11], [@CR12]\]). TIEG1 is also known as KLF10 and belongs to the Krüppel-like factors (KLF) family of proteins, constituting more than 20 family members in humans, including Sp1 as the most well-known member \[[@CR13]\]. The C-terminal DNA-binding domain (DBD) of KLF family proteins consists of three highly conserved tandem Cys~2~His~2~ zinc finger motifs. Most KLF family proteins have similar affinity for different GC-rich promoter elements, and the amino acids that are predicted to interact with DNA are identical among several members. Importantly, competition for DNA binding has been reported for some of the factors (reviewed in \[[@CR13]\]). In addition to DNA binding, the zinc finger motifs may also function in protein-protein interactions and are the target for post-translational modifications such as phosphorylation, acetylation and O-linked β-*N*-acetyl glucose amine addition (hereafter referred to as *O*-GlcNAc) \[[@CR14]\]. The N-terminal regions of KLF family members are much less conserved, containing various transcriptional activation and/or repression domains. Thus, different family members vary broadly in their ability to regulate transcription. However, most members can function either as activators or repressors, depending on the specific cellular and promoter contexts \[[@CR11], [@CR13]\]. The KLF factor TIEG1 is reported to induce and repress the expression of multiple genes, including p21^Cip1/WAF1^, and to function as an inhibitor of cell proliferation and an inducer of apoptosis (reviewed in \[[@CR12]\]). TIEG1 is suggested to function as a tumour suppressor as its expression inversely correlates with the severity and stage of breast cancer \[[@CR15]\].

In the present study we show that TIEG1 is a substrate of the aPKCs ζ and ι/λ. Two amino acid residues in the DBD were mapped as the major targets for phosphorylation, S384 located in zinc finger 1 and T445 in zinc finger 3. Phosphorylation of S384 significantly reduced the DNA-binding activity, whereas the T445 phosphorylation enhanced the TIEG1-mediated transcriptional activation of the p21^Cip1/WAF1^ promoter. Importantly, both phosphorylations resulted in subnuclear redistribution of TIEG1, strengthening the observation that phosphorylation of these residues in the DBD affects protein-protein and/or protein-DNA interactions. We also show that in addition to TIEG1, the DBD of other members of the KLF family proteins may be regulated by phosphorylation mediated by the aPKCs.

Materials and methods {#Sec2}
=====================

Antibodies and reagents {#Sec3}
-----------------------

The following primary antibodies were used: rabbit polyclonal antibody to PKCζ (C-20) (SC-216), rabbit polyclonal antibody to GST (Z-5, SC-459) (Santa Cruz Biotechnology), rabbit polyclonal antibody to green fluorescent protein (GFP) (ab290) (Abcam), rabbit polyclonal to beta-actin (A2066) (Sigma-Aldrich), mouse monoclonal antibody to PKCλ (610207) and the secondary antibodies HRP-conjugated goat anti-rabbit IgG (554021), and goat anti-mouse IgG (554002) antibodies were purchased from BD Bioscience Pharmingen. PKCι, active (14-505) and PKCζ, active (14-525) are purchased from Upstate.

Yeast two-hybrid screen {#Sec4}
-----------------------

The yeast two-hybrid screen was carried out with the Matchmaker system (Clontech) according to the manufacturer's instructions. The regulatory domain of PKCλ (pGBKT7-PKCλreg) fused to the Gal4 DBD was used as bait. This bait was transformed into *Saccharomyces cerevisiae* strain PJ69-2A (Clontech) and then mated with the Y187 strain pretransformed with a HeLa cell cDNA library fused to the Gal4 activation domain (Clontech). Approximately 10^6^ diploids were screened and tested for their ability to grow on yeast minimal medium lacking leucine, tryptophane, histidine, and adenine. Positive colonies were lysed by incubating them for 1--2 h in a glucuronidase-containing buffer \[(50 mM Tris-HCl (pH 7.5), 10 mM EDTA, 0.3% (v/v) β-mercaptoethanol, and 1:50 glucuronidase (G7017, Sigma)\] followed by vortexing with glass beads (G1145, Sigma) for 5 min. The lysates were diluted with 100 μl H~2~O, centrifuged briefly in a microcentrifuge at maximum speed, and 2 μl of each sample was analyzed by PCR using the REDTaq ReadyMix (R2523, Sigma). The PCR products were treated with exonuclease I (USB) and shrimp alkaline phosphatase (M820A, Promega) followed by sequencing using the BigDye sequencing kit (Applied Biosystems). The sequenced products were identified by searching the National Center for Biotechnology Information (NCBI) using the basic local alignment search tool (BLAST) algorithm. In order to verify specific interactions, clones were re-screened as described previously \[[@CR16]\].

Plasmids {#Sec5}
--------

Plasmids used in this work are listed in Table [1](#Tab1){ref-type="table"}. Point mutations were generated using the QuickChange site directed mutagenesis kit (Stratagene), and Gateway destination plasmids were made using Gateway LR recombination reactions (Invitrogen) following the manufacturer's instructions. All plasmid constructs made in this study were verified by DNA sequencing (BigDye sequencing kit, Applied Biosystems). The oligonucleotides used for mutagenesis, PCR, and DNA sequencing were purchased from Operon. Table 1Plasmids used in this studyVectorsDescriptionSourcepENTR3CGateway entry vectorInvitrogenpDONR207Gateway donor vectorInvitrogenpDest15Bacterial GST fusion expression vector; T7 promoterInvitrogenpGEX-4T-1Bacterial GST fusion expression vector; tac promoterAmershampDest53Mammalian GFP fusion expression vector; CMV and T7 promoterInvitrogenpDestTH1Bacterial MBP fusion expression vector; tac promoter\[[@CR59]\]pDestEGFP-C1Mammalian EGFP fusion expression vector; CMV promoter\[[@CR60]\]pDestMycMammalian Myc fusion expression vector; CMV and T7 promoter\[[@CR60]\]pDestHAMammalian HA fusion expression vector; CMV promoter\[[@CR60]\]pGEX-KG-SKS-Sp1(DBD)Bacterial GST fusion expression vector; tac promoter\[[@CR61]\]pGEX-KG-SKS-BTEB1(DBD)Bacterial GST fusion expression vector; tac promoter\[[@CR61]\]pGEX-KG-SKS-Sp3(DBD)Bacterial GST fusion expression vector; tac promoter\[[@CR61]\]pGEX-KG-SKS-BTEB2(DBD)Bacterial GST fusion expression vector; tac promoter\[[@CR61]\]p21-Luc\[[@CR56]\]pDestMyc-PKCλMurine PKCλ in entry vector\[[@CR60]\]**cDNA constructs made by traditional cloning or site directed mutagenesis**pDONR207-TIEG1Human TIEG1(1--480) in donor vectorThis studypENTR3C-TIEG1(1--362)Human TIEG1(1--362) in entry vectorThis studypENTR3C-TIEG1(DBD)Human TIEG1(363--480) in entry vectorThis studypENTR3C-Sp1Human Sp1(1--785) in entry vectorThis studypENTR3C-KLF4Human KLF4 (1--470) in entry vectorThis studypENTR3C-KLF4(DBD)Human KLF4 (381--470) in entry vectorThis studypENTR3C-Egr1Human Egr1(1--543) in entry vectorThis studypENTR3C-TIEG1(1--362)Sp1(DBD)Human TIEG1(1--362)Sp1(619--714) in entry vectorThis studypENTR3C-TIEG1(DBD)S384AHuman TIEG1(363--480) with S384A point mutation in entry vectorThis studypENTR3C-TIEG1(DBD)T445AHuman TIEG1(363--480) with T445A point mutation in entry vectorThis studypENTR-TIEG1(DBD)S384A/T445AHuman TIEG1(363--480) with S384A/T445A point mutations in entry vectorThis studypENTR3C-TIEG1(DBD)S384EHuman TIEG1(363--480) with S384E point mutation in entry vectorThis studypENTR3C-TIEG1(DBD)T445EHuman TIEG1(363--480) with T445E point mutation in entry vectorThis studypENTR3C-TIEG1(DBD)S384E/T445EHuman TIEG1(363--480) with S384E/T445E point mutations in entry vectorThis studypDONR207-TIEG1S384AHuman TIEG1 with S384A point mutation in donor vectorThis studypDONR207-TIEG1T445AHuman TIEG1 with T445A point mutation in donor vectorThis studypDONR207-TIEG1S384A/T445AHuman TIEG1 with S384A/T445A point mutations in donor vectorThis studypDONR207-TIEG1S384EHuman TIEG1 with S384E point mutation in donor vectorThis studypDONR207-TIEG1T445EHuman TIEG1 with T445E point mutation in donor vectorThis studypDONR207-TIEG1S384E/T445EHuman TIEG1 with S384E/T445E point mutations in donor vectorThis studypGEX-KG-SKS-Sp1(DBD)S641AHuman Sp1(DBD) with S641A point mutation in expression vectorThis studypGEX-KG-SKS-Sp1(DBD)S702AHuman Sp1(DBD) with S702A point mutation in expression vectorThis studypGEX-KG-SKS-Sp1(DBD)S641A/S702AHuman Sp1(DBD) with S641A/S702A point mutations in expression vectorThis studypGEX-KG-SKS-Sp1(DBD)S641E/S702EHuman Sp1(DBD) with S641E/S702E point mutations in expression vectorThis studypENTR-PKCλ regMurine PKCλ (1--247) in entry vectorThis study**cDNA constructs made by Gateway LR reaction (this study)**pDestMyc-PKCλpDest15-TIEG1(DBD)S384ApDest53-TIEG1(DBD)pDestGBKT7-PKCλ regpDest15-TIEG1(DBD)T445ApDestHA-TIEG1pDestEGFP-TIEG1S384ApDest15-TIEG1(DBD)S384A/T445ApDestHA-KLF4pDestEGFP-TIEG1T445ApDest15-TIEG1(DBD)S384EpDestHA-Sp1pDestEGFP-TIEG1S384A/T445ApDest15-TIEG1(DBD)T445EpDest3X-FLAG-Sp1pDestEGFP-TIEG1S384EpDest15-TIEG1(DBD)S384E/T445EpDestMyc-TIEG1(1--362)Sp1(DBD)pDestEGFP-TIEG1T445EpDestTH1- TIEG1pDestMyc-KLF11pDestEGFP-TIEG1S384E/T445EpDestTH1- TIEG1S384ApDestHA-KLF11pDest15-TIEG1pDestTH1- TIEG1T445ApDestEGFP-EGR1pDest15-TIEG1(1--362)pDestTH1- TIEG1S384A/T445ApDest15-TIEG1(DBD)pDest15-KLF4(DBD)

Cell culture and transfections {#Sec6}
------------------------------

HeLa cells and U2OS cells were maintained in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal calf serum (FCS), penicillin (100 U/ml) and streptomycin (100 μg/ml). Subconfluent cells were transfected with the different expression constructs using either Lipofectamine Plus (Invitrogen) or Metafectene Pro (Biontex) as recommended by the manufacturers.

Immunoprecipitations and immunoblots {#Sec7}
------------------------------------

Transfected cells were rinsed with ice-cold PBS prior to lysis in RIPA buffer \[50 mM Tris-HCl, pH 7.5, 150 mM NaCl, 1 mM EDTA, 1% NP-40 (v/v), 0.25% Triton X-100 (v/v)\] supplemented with Complete Mini EDTA-free protease inhibitor cocktail tablets (1 tablet per 10 ml) (11836170001, Roche Applied Science). Lysates were cleared by centrifugation followed by 30-min incubation with protein A-agarose beads (SC-2001, Santa Cruz Biotechnology). The precleared lysates were then incubated with the indicated primary antibodies overnight at 4°C and then with Protein A-agarose beads for an additional 1 h. Precipitated immunocomplexes were washed five times with RIPA buffer, eluted by boiling for 5 min in SDS-PAGE loading buffer. Samples were subsequently resolved by SDS-PAGE and transferred to Hybond-ECL nitrocellulose membranes (Amersham). After blocking unspecific binding sites by incubating the membranes for 1 h in 5% (w/v) non-fat dry milk in TBST \[10 mM Tris-HCl (pH 7.5), 150 mM NaCl, 0.1% (v/v) Tween 20\], blots were probed with the indicated primary antibodies overnight at 4°C and then by horseradish peroxidase-conjugated secondary antibodies for 1 h at room temperature. The membranes were washed six times (5 min each) with TBST prior to detection with Western Blotting Luminal Reagent kit (SC-2048, Santa Cruz Biotechnology) and a LumiAnalyst imager (Roche Applied Sciences).

GST pulldown assays {#Sec8}
-------------------

GST protein was expressed in *Escherichia coli* LE392 and MBP in *E. coli* DB 3.1. GST and MBP-tagged proteins were expressed in *E. coli* BL21 STAR (DE3)pLysS cells (Invitrogen). GST and GST-fusion proteins were purified and immobilized on glutathione-coupled sepharose beads (Glutathione-sepharose 4 Fast Flow, Amersham Bioscience). MBP and MBP-tagged proteins were purified using amylose resin (New England Biolabs). GST pulldown assays were performed by incubating GST and GST-fusion proteins either with in vitro translated proteins or with mammalian cell lysate. ^35^S-labeled proteins were produced using the TNT T7 Quick Coupled Transcription/Translation System (Promega) in the presence of \[^35^S\] methionine (Amersham Biosciences). The synthesized proteins were diluted 20× with NET-N buffer (20 mM Tris-HCl, pH 8.0, 100 mM NaCl, 1 mM EDTA, 0.5% Nonidet P-40) containing Complete Mini EDTA-free protease inhibitor cocktail. The diluted products were pre-cleared by incubating with glutathione-coupled sepharose beads for 30 min prior to incubation with purified GST or GST-fusion proteins for at least 2 h at 4°C with gentle agitation. Unbound proteins were removed by washing the resins five times with NET-N buffer. The proteins were then eluted by boiling for 5 min in SDS gel loading buffer and separated by SDS-PAGE. After vacuum drying the gel, ^35^S-labeled proteins were detected on a Fujifilm bioimaging analyzer BAS-5000 (Fuji). Lysates were prepared from confluent HeLa cells in 100 mm culture dishes as indicated above, except that glutathione-coupled agarose beads were used instead of protein A-agarose beads. Pulldown of PKCι/ζ from precleared HeLa cell lysates was also done as described for pulldown of ^35^S labeled proteins, except that proteins separated by SDS-PAGE were subjected to immunoblot analysis.

In vitro phosphorylation assays {#Sec9}
-------------------------------

In vitro phosphorylation assays of TIEG1 and its mutants by the aPKCs were carried out in a total volume of 30 μl, containing kinase buffer \[35.5 mM Tris-HCl (pH 7.5), 10 mM MgCl, 0.5 mM EGTA (pH 8.0), 0.1 mM CaCl~2~, Complete Mini EDTA-free protease inhibitor cocktail and phosphatase inhibitor cocktail set II (1:100) (524625, Calbiochem)\] and 50 ng recombinant active kinase. The enzyme reactions were initiated by the addition of 60 μM unlabeled ATP and 2 μCi \[γ-^32^P\] ATP (Amersham). After incubation at 30°C for 20 min, the reactions were terminated by the addition of SDS gel loading buffer and subsequent boiling for 5 min. The phosphorylated proteins were then analyzed by SDS-PAGE and autoradiography. The time courses of in vitro phosphorylations by PKCζ were performed by preparing 90 μl enzyme reactions and by withdrawing a 7-μl aliquot at the desired time points. The aliquots were transferred to microcentrifuge tubes containing SDS gel loading buffer and analyzed as described above. Where indicated, quantifications of the phosphorylated proteins and the corresponding background bands were done using the Fuji Image Gauge software (version 4.0; Fujifilm, Tokyo, Japan). The results are presented as bar graphs after background subtraction.

Gel mobility shift assay (GMSA) {#Sec10}
-------------------------------

The following two sets of oligonucleotides (shown 5′ to 3′) were used for GMSA: set I (for TIEG1) described in \[[@CR17]\] and set II (for KLF4 and Sp1) described in \[[@CR18]\].

Set I: 5′-TGCAGTGAAAAGGGGGTGTGTCAGGATGC-3′, and 5′-TGCATC CTGACACACCCCCTTTTCACTGC-3′; set II: 5′-CTTAACATTCCTTTCCCCACCCACACAGCTAGTTCCAACC-3′, and 5′-GGTTGGAACTAGCTGTGTGGGTGGGGAAAGGAATGTTAAG -3′. The DBDs of TIEG1, Sp1 and KLF4 were expressed and purified as described above and eluted in 50 mM Tris-HCl (pH 8.0) containing 10 mM reduced glutathione. The sense and antisense strands were annealed in annealing buffer \[10 mM Tris-HCl (pH 8.0), 1 mM EDTA and 100 mM NaCl\] and annealed by heating to 100°C for 3 min and cooling gradually to room temperature. The probes were labeled with \[γ-^32^P\] ATP using T4 polynucleotide kinase (Takara) and then purified and eluted using QIA quick nucleotide removal kit (QIAGEN) as per the recommendation of the manufacturer. The binding reaction mixtures, containing approximately 500 ng to 1 μg protein, 1 μg poly (dI-dC) and binding buffer \[for TIEG1: 4% Ficoll, 10 mM HEPES (pH 7.9), 30 mM KCl, 0.1 mM EDTA, 1 mM Na~2~HPO~4~, 4 mM spermidine and 0.5 mM DTT; and for KLF4 and Sp1: 4% Ficoll, 10 mM HEPES (pH 7.9), 60 mM KCl, 1 mM EDTA, and 1 mM DTT\] were incubated at room temperature for 10 min and then mixed with 3--4 × 10^4^ cpm of each probe and incubated for an additional 20 min. The DNA-protein complexes were resolved on pre-run 5% polyacrylamide gels (39:1) in 0.5× TBE buffer (44.5 mM Tris, 44.5 mM boric acid and 2 mM EDTA) at 230 v for 3 h. Where indicated, GST-tagged proteins were incubated with 100 ng of active PKCζ for 45 min prior to GMSA under the aforementioned kinase reaction conditions except for the omission of \[γ-^32^P\] ATP from the reaction mixture.

Cell imaging {#Sec11}
------------

Cells were seeded at a density of 10^4^ cells/well in eight-well coverglass slides (Nunc) and transfected with 100 ng plasmid expression vectors 24 h later using lipofectamin Plus (Invitrogen). One day after transfection cells were analyzed by live cell confocal microscopy using a Zeiss Axiovert 200 microscope with a 40×, 1.2 W C-Apochroma objective, equipped with an LSM510-META confocal module using the LSM 5 software version 3.2 (Carl Zeiss Inc.).

Fluorescence recovery after photobleaching (FRAP) {#Sec12}
-------------------------------------------------

FRAP experiments were carried out with cells plated and transfected as described above and imaged using a Leica TCS SP5 confocal microscope, 63×, 1.2 W objective, equipped with an incubation chamber with CO~2~ and temperature control. Cells were imaged with an argon 488-nm laser at 50% laser power and a pinhole setting of one. A circular area of 5 μM in diameter of the cell nucleus was analyzed using the following conditions: 5 prebleach images per 0.113 s, 10 bleach pulses per 0.113 s, 300 postbleach images per 0.113 s, 50 postbleach images per second and finally 45 postbleach images per 5 s. For imaging, laser power was attenuated to 5% of bleach intensity. A total of ten cells were analyzed per plasmid construct for each independent experiment, and the experiments were performed at least three times. Individual FRAP curves were background subtracted and corrected for loss of fluorescence caused by photobleaching during imaging.

Reporter gene assays {#Sec13}
--------------------

U2OS cells were seeded at a density of 4 × 10^4^ cells/well in 24-well plates and transfected 24 h later using Metafectene Pro. Transfections were performed with 100 or 250 ng of the various protein expression plasmids together with 100 ng of the reporter p21LUC. The β-galactosidase expressing pCMV-βgal vector (50 ng) (Stratagene) was included to determine transfection efficiency. Cells were harvested 24 h post transfection and luciferase activities measured using the dual light luciferase and β-galactosidase kit (TROPIX) on a Luminoskan RT dual injection luminometer (Labsystems). All reporter gene assays were carried out in independent triplicate experiments and repeated at least three times. The luciferase values varied 1--12% among the parallels.

Results {#Sec14}
=======

The aPKCs ι/λ and ζ interact with the zinc finger DBD of the Krüppel-like transcription factor family {#Sec15}
-----------------------------------------------------------------------------------------------------

In an attempt to find novel interaction partners for the aPKCs, we performed a yeast two-hybrid screen using a HeLa cell cDNA expression library together with the regulatory domain of PKCλ as bait. Three out of 68 positive clones were identified as the C-terminal zinc finger region of the Krüppel-like transcription factor TIEG1 (Fig. [1](#Fig1){ref-type="fig"}a). The interaction was confirmed in vitro by GST pulldown assays using GST fusions of the zinc finger DBD of TIEG1 (TIEG1(DBD)) and the N-terminal proline-rich region of TIEG1 (TIEG1(1--362)), and in vitro translated PKCλ. As can be seen from Fig. [1](#Fig1){ref-type="fig"}d, no interaction was detected with the N-terminal part of TIEG1. To further evaluate the interaction between full-length TIEG1 and full-length PKCι GST pulldown assays with GST-TIEG1 and whole-cell extract isolated from HeLa cells were performed. Western blot analysis of the pulled-down proteins with an antibody recognizing both PKCι and PKCζ showed that both kinases interact with full-length TIEG1 (Fig. [1](#Fig1){ref-type="fig"}b). Finally, co-immunoprecipitation assay using U2OS cells overexpressing EGFP-TIEG1 verified that TIEG1 and PKCι interacted in HeLa cells (Fig. [1](#Fig1){ref-type="fig"}c).Fig. 1PKCs ζ and ι interact with the KLF family zinc finger domain in vitro and in HeLa cells. **a** Schematic representation of the domain structure of TIEG1. The three zinc finger motifs constituting the DNA-binding domain are represented by *filled boxes*. The TIEG1 region isolated in the yeast two-hybrid screen is indicated by the *solid line* below the schematic. **b** Whole-cell extracts from HeLa cells were incubated with equal amounts of bacterially expressed GST or GST-TIEG1 immobilized on glutathione-sepharose beads. The presence of aPKCs in the pulled-down proteins were examined by immunoblotting using αPKCζ(C20) antibody that recognizes both PKCζ and PKCι. **c** U2OS cells were transfected with either GFP or GFP-TIEG1. The cells were lysed 24 h post transfection, and immunoprecipitations were performed using anti-GFP antibody. Western blots of the immunoprecipitates and of the cell extract were revealed using monoclonal anti-PKCλ antibody (*left panel*) and immunoprecipitated GFP or GFP-TIEG1 proteins were visualized using polyclonal anti-GFP antibody (*right panel*). d Myc-tagged PKCλ was in vitro translated in the presence of \[^35^S\] methionine and incubated with equal amounts of either glutathione-sepharose beads coupled GST or GST-tagged KLF family proteins. The pulled-down proteins together with 5% of the input were subjected to detection by autoradiography (*upper panel*). The levels of GST or GST-tagged proteins used in the GST pulldown assays were examined by Coomassie brilliant blue staining (*lower panel*). The data shown in **b**, **c**, and **d** correspond to a representative experiment out of two performed

TIEG1 is a member of the KLF family of three zinc finger proteins. The three zinc fingers constitute the DBD, which is highly conserved within the KLF family. In addition to DNA binding, the zinc finger motifs may also function in protein-protein interactions that modulate DNA-binding specificity \[[@CR13]\]. Thus, to determine whether PKCλ had the ability to interact with other members of the KLF family, we conducted GST pulldown assays with PKCλ and the KLF family proteins Sp1, Sp3, BTEB1 and BTEB2. Interestingly, PKCλ was found to interact with the DBD of all KLF family proteins tested (Fig. [1](#Fig1){ref-type="fig"}d), suggesting that aPKCs may be general interaction partners of KLF family proteins.

The KLF family of transcription factors are substrates for atypical PKCι and ζ in vitro {#Sec16}
---------------------------------------------------------------------------------------

The Krüppel-like transcription factor Sp1 has been reported to be a target for PKCζ-mediated phosphorylation in several reports (reviewed in \[[@CR14]\]). The interaction between TIEG1 and the aPKCs ι and ζ raised the question whether TIEG1 is also a substrate for these kinases. Full-length TIEG1 expressed as a MBP fusion in *E*. *coli* was incubated with recombinant PKCι or PKCζ in an in vitro kinase assay. Both kinases had the ability to phosphorylate TIEG1 (Fig. [2](#Fig2){ref-type="fig"}a), and the phosphorylation increased linearly within a time period of 90 min (Fig. [2](#Fig2){ref-type="fig"}b). We also included the KLF proteins KLF4 and the closely related KLF11 (also called TIEG2) in a phosphorylation assay. Both proteins were PKCι/ζ substrates (Fig. [2](#Fig2){ref-type="fig"}c and data not shown), supporting the notion that the aPKCs are putative regulators of KLF family proteins. To determine whether the zinc finger DBD or the N-terminal proline-rich regions were substrates for the aPKCs, each of these regions was expressed as GST fusions and incubated with recombinant PKCζ in an in vitro kinase assay. The N-terminal proline-rich region of TIEG1 was clearly not a PKCζ substrate, whereas the zinc finger DBD was heavily phosphorylated (Fig. [2](#Fig2){ref-type="fig"}e).Fig. 2The KLF family proteins are phosphorylated by the atypical PKCs ζ and ι. **a**, **c** Both PKCζ and PKCι phosphorylate TIEG1 (**a**) and KLF4 (**c**) in vitro. The phosphorylation assays were performed for 20 min at 30°C in 30-μl reaction volume containing MBP, and MBP-TIEG1 or MBP-KLF4 as substrate, 50 ng recombinant active PKCζ (*upper panels*) or PKCι (*lower panels*) 60 μM unlabeled ATP and 2 μCi \[^32^P\]-ATP. The reactions were analyzed by autoradiography. **b**, **d** The phosphorylation of TIEG1 (**b**) and KLF4 (**d**) by PKCζ is linear with time. The *upper panels* are bar graphs showing the quantification of the phosphorylation levels of TIEG1 and KLF4 over the indicated time points, respectively, and the *lower panels* are the corresponding autoradiographs. **e**, **f** The DNA-binding domains of KLF family proteins are targets for PKCζ-mediated phosphorylation. GST, GST-TIEG1(1--362) and GST-TIEG1(DBD) (**e**), and GST, GST-tagged DBDs of KLF family proteins (**f**) were subjected to in vitro phosphorylation and subsequent analysis by autoradiography. The data in **a**, **c**, **e** and **f** are representative of three independent experiments. The data in **b** and **f** are shown as the mean (± SD) of four independent experiments

The fact that the conserved DBD of TIEG1 is a PKCsι/ζ substrate encouraged us to investigate whether this would be the case for the DBD of the KLF transcription factors found to interact with PKCι and ζ in this study. All four KLFs were PKCι/ζ substrates in vitro (Fig. [2](#Fig2){ref-type="fig"}f). Sp1(DBD), which is a known PKCζ substrate, and BTEB1(DBD) were more heavily phosphorylated than Sp3(DBD) and BTEB2(DBD). Taken together, the results suggest that the aPKCs may regulate KLF family proteins by phosphorylating their DBDs.

S384 and T445 of TIEG1 are phosphorylated by PKCζ {#Sec17}
-------------------------------------------------

As mentioned above, the zinc finger DBD of the KLF factors are highly conserved (Fig. [3](#Fig3){ref-type="fig"}a). Four residues within the DBD of Sp1 are reported to be phosphorylated by PKCζ: S641 in zinc finger 1, and T668, S670 and T681 in zinc finger 2 (reviewed in \[[@CR14]\]). Phosphorylation of S641 leads to release of the inhibitor p107 from Sp1 bound to the luteinizing hormone receptor (LHR) promoter, thereby activating transcription of the LHR \[[@CR19]\]. T668, S670 and T681 in zinc finger 2 are phosphorylated by PKCζ upon angiotensin II stimulation, leading to activation of the PDGF-D promoter \[[@CR20]\]. In order to map the specific residues in TIEG1 phosphorylated by PKCζ, we chose to focus on S384, which is positioned in the recognition helix of zinc finger 1 similarly to S641 of Sp1 (Fig. [3](#Fig3){ref-type="fig"}a), and T445 located in the recognition helix of zinc finger 3. None of these residues are involved in direct contact with DNA bases, but they are positioned next to amino acids that are important for sequence-specific DNA binding (Fig. [3](#Fig3){ref-type="fig"}a). Substitution of S384 and T445 with alanine significantly reduced the PKCζ-mediated phosphorylation of the TIEG1 DBD in an in vitro phosphorylation assay (Fig. [3](#Fig3){ref-type="fig"}b). This was confirmed by introducing the same alanine substitutions into the full-length TIEG1 protein (supplementary material Fig. S1), where the single alanine mutants led to reduction in the phosphorylation of TIEG1. However, introducing the double mutations did not lead to a complete loss of PKCζ mediated phosphorylation (supplementary material Fig. S1). This suggests that other serine and/or threonine residues within the TIEG1 DBD may act as substrates for this kinase. T445 is located in the same position as S702 in Sp1. This residue is not a known PKCζ substrate. In order to investigate whether Sp1 S702 was a PKCζ target, an Sp1 S702A mutant was subject to an in vitro phosphorylation assay. Interestingly, PKCζ-mediated phosphorylation of the Sp1 S702A mutant was reduced to a similar degree as that of the well-known Sp1 S641A mutant (Fig. [3](#Fig3){ref-type="fig"}c), indicating Sp1 S702 as a novel target for PKCζ. The mapping of the Sp1 S702 and TIEG1 T445 residues as targets for PKCζ also explains why the Sp3- and BTEB2 DBDs were less phosphorylated than the Sp1- and TIEG1 DBDs (Fig. [2](#Fig2){ref-type="fig"}f). The Sp3- and BTEB2 DBDs have an A at the site corresponding to Sp1 S702 and TIEG1 T445 (Fig. [3](#Fig3){ref-type="fig"}a). Taken together, these results show that conserved serine and threonine residues within the recognition helices of zinc fingers 1 and 3 of TIEG1 and Sp1 are potential targets for PKCζ mediated phosphorylation.Fig. 3PKCζ phosphorylates TIEG1 at Ser 384 located in zinc finger 1 and Thr 445 located in zinc finger 3. **a** Amino acid sequence alignment of the DBDs of the KLF family proteins. Conserved residues are *shaded*, and the core zinc finger domains are indicated by *thick lines* and labeled *ZF 1--3*. The locations of the phospho-acceptors Ser 384 and Thr 445 residues are *boxed*. *Below* and to the *left* is the structure of the zinc finger protein ZNF268 \[[@CR57]\] with the location of the phosphorylation sites in the recognition helixes of zinc fingers 1 and 3 indicated by *arrows*. *Below* and to the *right* are the amino acid sequences of zinc fingers 1 and 3 in TIEG1. The amino acids within the recognition helix that are proposed to contact the DNA bases are indicated by *solid lines*. The prediction is based on the NMR structure of Sp1 \[[@CR58]\]. Ser 384 and Thr 445 are shown in *bold*. **b**, **c** Mutations of TIEG1S384 and TIEG1T445 (**b**), and Sp1S641 and Sp1S702 (**c**) to alanine significantly reduce their PKCζ-mediated phosphorylation. Equal amounts of GST and GST-tagged TIEG1 proteins (**b**), GST and GST-tagged Sp1 proteins (**c**) were subjected to in vitro phosphorylation assays; detection and quantification as described above. Shown are the quantified phosphorylation levels as bar graphs (*upper panels*), autoradiographs (*middle panels*) and *Coomassie staining* indicating the levels of GST and GST-tagged proteins used in the in vitro kinase assays (*lower panels*). Each *bar* in **b** and **c** represents the mean (± SD) of four independent experiments

Phosphorylation of S384 inhibits the DNA-binding activity of TIEG1 {#Sec18}
------------------------------------------------------------------

PKCζ-mediated phosphorylation of Sp1 has been reported both to increase and decrease DNA binding (reviewed in \[[@CR14]\]). In order to investigate whether PKCζ-mediated phosphorylation of TIEG1 would compromise or stimulate DNA binding, we performed GMSA with the S384A and T445A mutants and the double mutant S384A/T445A. Both the single and double mutants seemed to have stronger affinity for DNA than the wild-type protein (Fig. [4](#Fig4){ref-type="fig"}a). To mimic phosphorylation of these residues, the S384E, T445E and S384E/T445E mutants were generated and used in GMSA. No DNA binding could be detected for the S384E and S384E/T445E mutants. The T445E mutant, however, bound DNA with similar affinity as the wild type. These results suggest that phosphorylation of S384 impairs DNA binding, while phosphorylation of T445 has no effect on DNA binding.Fig. 4PKCζ-mediated phosphorylation of TIEG1S384 impairs its DNA-binding activity. **a**--**c** Gel mobility shift assays (GMSA) demonstrating the effects of phospho-mimicking substitutions or in vitro phosphorylation on the DNA-binding ability of KLF proteins. **a** Substitution of Ser 384 to glutamate abolishes the DNA-binding ability of TIEG1. GMSA using GST and GST-fused TIEG1 proteins, and \[^32^P\]-ATP labeled oligonucleotides containing consensus TIEG1-binding sites described in \[[@CR17]\]. The binding reactions were separated on non-denaturating polyacrylamide gels that were vacuum dried and analyzed by autoradiography (*upper panel*). The *lower panel* shows control protein staining indicating the amounts of proteins used in the assays. **b** Pre-phosphorylation of TIEG1(DBD) by PKCζ also impairs DNA binding. Here, GST and GST-fused TIEG1 proteins were pre-incubated with PKCζ in the presence or absence of ATP prior to GMSA. **c** PKCζ-mediated phosphorylation of the DBDs of KLF4 and Sp1 does not impair their DNA-binding activity. GMSA with GST and GST-KLF4(DBD) (*left panel*), and GST and GST-tagged Sp1proteins (*right panel*). The proteins were pre-treated with PKCζ and/or ATP prior to GMSA using \[^32^P\]-ATP labeled oligonucleotide containing consensus KLF-binding sites described in \[[@CR18]\]. The data shown are representative of three independent experiments

In order to determine whether TIEG1 DBD phosphorylated by PKCζ would have similar DNA-binding properties as the S384E/T445E mimicking mutant, the TIEG1 DBD wild-type and double alanine mutant versions were phosphorylated by PKCζ before performing gel shift assays. Pre-phosphorylated TIEG1 DBD binds DNA with significantly less affinity than the unphosphorylated forms (Fig. [4](#Fig4){ref-type="fig"}b). Notably, the phosphorylated TIEG1 DBD S384A/T445A mutant showed less affinity for DNA than the unphosphorylated forms, indicating the presence of additional PKCζ phosphorylation sites within the TIEG1 DBD. Furthermore, the effects of PKCζ-mediated phosphorylation on DNA binding were investigated for the KLF family proteins Sp1 and KLF4. Surprisingly, phosphorylation of the KLF4 and Sp1 DBDs did not seem to affect DNA binding at all (Fig. [4](#Fig4){ref-type="fig"}c). Hence, PKCζ phosphorylation of the DBDs of KLF family proteins may increase, decrease or have no effect on DNA-binding activity depending on the specific KLF protein and the specific phosphorylation site involved. For instance, as shown here, phosphorylation of TIEG1 S384 in the recognition helix of zinc finger 1 clearly impaired its DNA-binding activity.

The phospho-mimicking mutants of TIEG1 display a redistributed subnuclear localisation {#Sec19}
--------------------------------------------------------------------------------------

To explore whether phosphorylation of S384 and/or T445 had an impact on the nuclear localization of TIEG1, GFP fusions of wild-type TIEG1 and the six mutants S384A, S384E, T445A, T445E, S384A/T445A and S384E/T445E were expressed in HeLa and U2OS cells. The subcellular distribution of the GFP-fusion proteins was investigated by confocal fluorescence microscopy. In both cell lines, wild-type TIEG1 is localized in the nucleus but excluded from the nucleoli, with a weak staining in the nucleoplasm and enrichment in several specific irregular speckles or bodies (Fig. [5](#Fig5){ref-type="fig"}a, upper panels). Interestingly, GFP-TIEG1 S384E or GFP-TIEG1 T445E was redistributed into specific round nuclear bodies (Fig. [5](#Fig5){ref-type="fig"}a, middle panels). This redistribution into round nuclear bodies is most prominent for the double mutant GFP-TIEG1 S384E/T445E (Fig. [5](#Fig5){ref-type="fig"}a, lower panels), and the phenotype is displayed by about 50% of the transfected cell population. To address the question whether the observed subnuclear redistributions are a simple consequence of overexpression or not, we performed fluorescence recovery after photobleaching (FRAP) analysis with the wild-type and the double mutant forms of GFP-TIEG1. As shown in Fig. [5](#Fig5){ref-type="fig"}b, the round nuclear dots of GFP-TIEG1 S384E/T445E are not simple aggregates since their mobility is similar to that of the wild type and the S384A/T445A mutant. Taken together, these results suggest that phosphorylation of TIEG1 DBD may recruit the protein to specific dynamic nuclear structures.Fig. 5Mutation of TIEG1 Ser 384 and Thr 445 to glutamate induces subnuclear relocalization. **a** The phospho-mimicking mutants of TIEG1 are enriched in round nuclear bodies. HeLa and/or U2OS cells were transfected with an expression construct for EGFP-TIEG1 or EGFP-tagged TIEG1 mutants and imaged by confocal laser fluorescence microscopy 24 h post transfection. **b** The TIEG1 mutants display mobility similar to the wild-type TIEG1. HeLa cells were transfected with the indicated constructs, and 24 h post transfection the cells were imaged and fluorescence signals were collected before and after photobleaching a portion of the nucleus. The recovery kinetics were calculated after double normalization of the initial fluorescence, corrected for background and loss of fluorescence caused by imaging. The graph presented here shows the average intensity of the bleach spot of 9--10 independent cells for the indicated time points. *Error bars* represent the SD values between various experiments

Phosphorylation of T445 enhances the transactivation potential of TIEG1 {#Sec20}
-----------------------------------------------------------------------

Overexpression of TIEG1 is shown to mimic TGFβ activity in several cell lines \[[@CR21]--[@CR23]\] and to enhance TGF-β1 expression \[[@CR24]\]. TIEG1 has also been found to increase TGFβ-induced expression of the cyclin-dependent kinase inhibitor p21^Cip1/WAF1^ \[[@CR22]\]. Here, we conducted reporter gene assays using the p21^Cip1/WAF1^ promoter cloned in front of the luciferase gene to determine whether the phosphorylation of TIEG1 DBD at S384 and/or T445 would impact its transactivation potential. As shown in Fig. [6](#Fig6){ref-type="fig"}a, overexpression of wild-type TIEG1 increased luciferase expression from the p21 ^Cip1/WAF1^ promoter six- to nine-fold. The transactivation was strongly increased up to 25-fold when TIEG1 containing the T445E mutation was coexpressed, suggesting that phosphorylation of T445 positively regulates its transcriptional activation potential. Consistent with this notion, we observed a reduction in the luciferase activity when the T445A mutant was co-expressed. Surprisingly, the S384E and the S384E/T445E mutants, which we found had lost their DNA-binding activity, still had the capacity to stimulate expression from the p21^Cip1/WAF1^ promoter (Fig. [6](#Fig6){ref-type="fig"}a). A likely explanation for this observation is that the mutants with compromised DNA-binding activity are recruited to the promoter by endogenous TIEG1 and/or other KLF family proteins. The p21^Cip1/WAF1^ promoter contains six adjacent GC boxes close to the transcriptional start site that have the potential to recruit KLF family proteins (Fig. [6](#Fig6){ref-type="fig"}a). We found that TIEG1 (and other KLF proteins too) has a strong capability to form homo- and heterodimers with KLF family proteins via interactions involving the DBDs (Fig. [7](#Fig7){ref-type="fig"}, and supplementary material Fig. S2). This interaction is not dependent on the presence of nucleic acids as evidenced by benzonase treatment (Fig. [7](#Fig7){ref-type="fig"}c, d). The homo- and heterodimerization potential of the TIEG1 DBD is not impaired by phosphorylation of S384 or T445 (supplementary material Fig. S3). Thus, TIEG1 mutants with impaired DNA-binding activity may be recruited to specific promoter sites by interaction with endogenous KLF factors bound to the promoter.Fig. 6The TIEG1T445E mutant displays enhanced transactivation potential. **a** U2OS cells were transiently transfected with 0.1 μg of the reporter p21-LUC, together with the expression vectors for TIEG1 and TIEG1 mutants as indicated and subjected to reporter gene assay analysis. The data represent the mean of two independent experiments performed in triplicates. *Error bars* represent the SD values between various experiments. **b** Total cell extracts from the transfected U2OS cells were prepared, and the levels of TIEG1 proteins were analyzed by Western blotting using anti-GFP antibody (*upper panel*) and then with anti-actin antibody as loading control (*lower panel*). **c** All KLF family proteins tested except KLF4 are potential activators of the p21^Cip1/WAF1^ promoter. The reporter gene assay data shown is from one experiment performed in triplicate, which is representative of three independent experiments each performed in triplicate. *Error bars* represent the SD values between the parallels. **d** Western blot analysis of extracts from transfected U2OS cells to show the expression level of the various KLF family proteinsFig. 7KLF family proteins have the ability to homo- and heterodimerize via their DNA-binding domain. **a**--**c** GST pulldown assays were carried out using bacterially expressed GST, or the indicated GST-tagged proteins, and in vitro translated either full-length HA-TIEG1 (**a**, **b**) or GFP-TIEG1(DBD) (**c**). Autoradiographs are presented in the *upper panels*, whereas Coomassie brilliant blue stained SDS-polyacrylamide gels are shown in the *lower panels*. **c**, **d** TIEG1 homodimerization is not mediated by nucleic acids in the reaction mixture. GFP-TIEG1(DBD) was in vitro translated and divided into two. One half was used directly for GST pulldown assays (**c**, *right panel*), and the remaining half was treated with 250 units of benzonase for 20 min at room temperature prior to GST pulldown assays (**c**, *left panel*). **d** The benzonase used in the assay was active. The expression construct, GFP-TIEG1(DBD), was either treated with benzonase or left untreated, and the reaction analyzed on a 0.7% agarose gel followed by ethdium bromide staining. Data shown are representative of two independent experiments

Sp1 is a well-known activator of the p21^Cip/WAF1^ promoter. Phosphorylation of Sp1 on T453, T739 \[[@CR25]\] or S59 \[[@CR26]\] has been shown to induce expression of p21^Cip1/WAF1^ and cellular senescence. Additionally, PKC \[[@CR27]\], PKG \[[@CR28]\] and high-glucose induced p21^Cip1/WAF1^ expression is mediated by Sp1 binding to the p21^Cip1/WAF1^ promoter. To examine whether other KLF family proteins were potential activators of the p21^Cip1/WAF1^ promoter, luciferase reporter assays were performed with KLF4, KLF11 and EGR1 in addition to Sp1 and TIEG1 (Fig. [6](#Fig6){ref-type="fig"}c). Both KLF11 and EGR1 induced expression from the p21^Cip1/WAF1^ promoter, KLF11 (TIEG2) with a similar potency as TIEG1. KLF4, on the other hand, did not cause significant activation of the promoter. When we replaced the DBD of TIEG1 with the DBD of Sp1, the hybrid transcription factor also induced the p21^Cip1/WAF1^ promoter although less potently than Sp1 and TIEG1. Furthermore, we found overexpression of EGR1 to be significantly less toxic than overexpression of TIEG1, Sp1 and KLF11 (data not shown), although EGR1 also induced p21^Cip1/WAF1^ expression. This suggests that apoptosis induced by Sp1-like family proteins may involve additional mechanisms besides p21^Cip1/WAF1^ upregulation. This correlates well with reports showing that TIEG1 induces apoptosis through the mitochondrial apoptotic pathway upregulating Bax and Bim, and downregulating Bcl-2 and Bcl-XL \[[@CR29]\], and KLF11 inducing oligodendroglial cell death by downregulation of Bcl-X expression \[[@CR30]\].

Discussion {#Sec21}
==========

In this study we have shown that TIEG1 is an interaction partner and substrate for aPKCs. Two residues in the DBD, S384 and T445 in zinc fingers 1 and 3, respectively, were found to be the major sites phosphorylated by recombinant aPKCs. Substitution of S384 by the phospho-mimicking glutamate (S384E) resulted in inhibition of DNA binding, while the T445E mutant displayed an enhanced transactivation potential relative to the wild-type protein. Both mutations led to a subnuclear redistribution of the protein into round, dynamic nuclear bodies. In addition, we show that the DBDs of various KLF family proteins are targets for PKCζ/ι-mediated phosphorylation and that the KLF proteins have a strong ability to form homo- and heterodimers via their DBDs.

Sp1 is phosphorylated by PKCζ \[[@CR20], [@CR31]--[@CR36]\] (reviewed in \[[@CR14]\]). PKCζ-mediated phosphorylation of S641 in zinc finger 1 of Sp1 does not affect its DNA-binding activity, but leads to release of the p107 inhibitor and thereby enhanced transcriptional activation \[[@CR36]\]. In contrast, here we report that PKCζ-mediated phosphorylation of TIEG1 at S384, which corresponds to S641 of Sp1, strongly inhibited DNA binding. However, the transcriptional activity of the TIEG1 S384E mutant on the p21^Cip1/WAF1^ promoter was less affected. This suggests that even if KLF family proteins are phosphorylated at corresponding amino acid residues, the biological outcome of the phosphorylation may be specific to the particular KLF factor involved.

We have also shown that corresponding residues in zinc finger 3 of TIEG1 and Sp1 are targets for PKCζ-mediated phosphorylation. The phospho-mimicking mutant TIEG1 T445E significantly enhanced TIEG1-induced activation of the p21^Cip1/WAF1^ promoter. Interestingly, Sp1 S702 is also reported to be modified by the monosaccharide O-linked β-*N*-acetylglucose amine (*O*-GlcNAc) \[[@CR37]\]. *O*-GlcNAcylation of Sp1 has been shown to increase \[[@CR37]--[@CR43]\] or decrease \[[@CR42], [@CR44]\] its transcriptional activity depending on the target promoter. *O*-GlcNAc and phosphate modifications on substrates are shown to interact in various ways both at the global cellular protein level and at specific sites on particular proteins (reviewed in \[[@CR45]\]). For instance, they can competitively and alternatively occupy the same serine or threonine residue, or they can regulate each other by generating large functional complexes. Hence, phosphorylation of Sp1 S702 may regulate and/or communicate with the *O*-GlcNAc modification of Sp1, and thereby also regulate its transcriptional activity. Furthermore, Sp1 S702 is located next to Sp1 K703, which is reported to be targeted for acetylation \[[@CR46]\]. Acetylation of Sp1 K703 recruits HDAC1 to the Sp1 located promoter sites and represses transcription, while deacetylated K703 recruits p300 and induces transcription. Hence, phosphorylation and/or glycosylation of S702 and acetylation of K703 may interact with each other in an agonistic or antagonistic manner, and thereby integrate diverse signaling cues at the transcriptional level through Sp1 bound at promoter sites. Interestingly, we also found TIEG1 to be modified by *O*-GlcNAc (E. Alemu and T. Johansen, unpublished data). *O*-GlcNAc modifications of proteins are believed to constitute an important regulatory pathway that controls protein activity according to glucose availability. *O*-GlcNAc modification of Sp1 has been connected to glucose sensing, expression of glucose transporters and in various aspects of hyperglycaemic-induced glucotoxicity (reviewed in \[[@CR47]\]), whereas TIEG1 is involved in the regulation of circadian gene expression, which is trigged by glucose \[[@CR48]\]. Interestingly, aPKCs are heavily involved in regulation of glucose transport and insulin sensitivity \[[@CR7]\]. Our in vitro data suggest that aPKCs at least partly may exert this regulation via post-translational modifications of Sp1 and TIEG1. Additionally, TIEG1 contains a lysine residue (K446), which lies next to the PKCζ targeted site (TIEG1 T445). Whether this lysine as well is a target for post-translational modifications, such as acetylation, has not been reported yet.

Overexpression of TIEG1 induces apoptosis by activating TGFβ-regulated signaling pathways \[[@CR23], [@CR49], [@CR50]\] (reviewed in \[[@CR12]\]) and promoting mitochondrial apoptotic pathways \[[@CR29]\]. TIEG1 overexpression is reported to increase the expression of the cyclin-dependent kinase inhibitor p21^Cip1/WAF1^ and significantly decrease cellular proliferation. Here we show that TIEG1 is a potent activator of the p21^Cip1/WAF1^ promoter and that a phospho-mimicking mutation of TIEG1 T445 significantly enhances this activation. In general, Sp1 family transcription factors are reported as major regulators of p21^Cip1/WAF1^ transcription (reviewed in \[[@CR51], [@CR52]\]). The p21^Cip1/WAF1^ promoter contains six binding sites for Sp1 family proteins at the proximal promoter (bp −120 to −50), and mutations of these sites significantly affect synergistic activation by Sp1, p53 and other signals that regulate transcription of the p21^Cip1/WAF1^ gene \[[@CR52], [@CR53]\]. Importantly, the transcriptional activity of Sp1 has been reported to be regulated by phosphorylation by various kinases at different sites, and these signaling events are integrated at GC-box containing promoters (reviewed in \[[@CR14]\]). We found that the aPKCs phosphorylate Sp1 and TIEG1 at corresponding sites in the DBD. Both proteins are reported to induce p21^Cip1/WAF1^ expression upon various stimuli, via the six promoter proximal GC boxes. GC box 3 is shown to mediate p21^Cip1/WAF1^ induction by agents such as TGFβ and histone deacetylase inhibitors, whereas GC boxes 1 and 2 are important for transcriptional activation mediated by phorbol esters and okadaic acid (reviewed in \[[@CR52]\]). The aPKCs are involved in cell polarity processes, metabolic regulation and cell survival signaling, and PKCι is also reported to act as an oncogene when its gene is amplified in lung and ovarian cancers (reviewed in \[[@CR4]\]). Hence, one would expect that aPKCs could have a negative effect on the suggested tumor suppressor TIEG1. This effect could be exerted via S384 phosphorylation. However, aPKC could also act positively via phosphorylation of T445. We found that the S384E/T445E double mutant strongly reduced the p21^Cip1/WAF1^ induction seen with the T445E mutant alone. The effect of aPKC phosphorylation of the TIEG1 DBD may therefore depend on the accessibility of these sites. The above-mentioned O-GlcNAcylation and acetylation may be involved in regulating this accessibility.

How post-translational modifications of Sp1 influence its affinity for DNA and other proteins is only beginning to become apparent. Sp1 can interact with components of the basal transcription machinery, as well as transcription factors, coactivators and corepressors. Several of these interactions are regulated by post-translational modifications of Sp1. This protein also has a strong tendency to interact with itself \[[@CR54]\] and with other members of the KLF protein family (this work). In addition, there is direct binding competition among KLF family proteins on GC-rich promoter sequences (\[[@CR55]\] and ref. therein). Our present results show that various activities of TIEG1 including DNA binding, transcriptional activation and subnuclear localization are also regulated by post-translational modifications, suggesting that this is most probably a general feature of KLF family proteins. Moreover, our data indicate that KLF family proteins may offer a large number of combinatorial possibilities to regulate expression from GC box containing promoters, making them important candidates for integrating various cellular signaling events at the transcriptional level.

Electronic supplementary material {#AppESM1}
---------------------------------

Below is the link to the electronic supplementary material.

###### 

Supplementary material 1 (PDF 334 kb)

###### 

Supplementary material 2 (PDF 825 kb)

###### 

Supplementary material 3 (PDF 835 kb)

We thank the BioImaging and Proteomics FUGE core facilities at the Institute of Medical Biology, University of Tromsø, for use of instrumentation and expert assistance. This work was supported in part by grants from the FUGE program of the Norwegian Research Council, the Norwegian Cancer Society and the Blix Foundation to T.J.

**Open Access** This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.
